AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

Stock Information for AVEO Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.